Clinical Trial Update: A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS [Phase 1, Phase 2]

View source ↗

Summary

A phase 1b/2 trial evaluating alvocidib in combination with decitabine or azacitidine in myelodysplastic syndromes was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Alvocidib (Flavopiridol)
• Decitabine (Decitabine)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Myelodysplastic Syndromes (MDS) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-10-21